{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:51:08Z","timestamp":1793332268607,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Minoxidil solution has routinely been used for decades for the treatment of androgenic alopecia. Central serous chorioretinopathy (CSCR) is a rare side-effect noted following prolonged topical minoxidil therapy for androgenic alopecia. In this report, we describe a case of a 41-year-old young man who developed CSCR following prolonged therapy with topical Minoxidil solution and was treated with oral eplerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 41-year-old male presented to the retina clinic with complaints of seeing a black spot, blurred vision and metamorphopsia involving the right eye for the past 4\u2009months. He was on treatment for androgenic alopecia with topical 5% Minoxidil application on scalp two times a day. He noticed the symptoms 8\u2009months after starting the treatment and had stopped the medication since the past 2\u2009months. On examination, best-corrected visual acuity was 20\/20 in both eyes. Fundoscopic examination of the right eye with +78D lens on slit lamp revealed the presence of subretinal fluid and few focal spots of retinal pigment epithelial alterations. Optical coherence tomography scan evaluation showed the presence of subretinal fluid (SRF) and pachychoroid supporting the diagnosis of CSCR. Indocyanine green angiography revealed dilated hyperpermeable choroidal vasculature on the nasal side of the fovea in the early and later phases of the angiogram. The patient was diagnosed with CSCR as a possible consequence of the topical minoxidil solution. Patient was asked to avoid future use of Minoxidil and was started on oral eplerenone therapy 50\u2009mg\/day for 4 consecutive weeks. One month later, there was complete resolution of his symptoms and SRF. At the final follow-up visit, 2\u2009months after starting the therapy, there was no recurrence of SRF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CSCR is a rare side-effect noted following prolonged topical minoxidil therapy for androgenic alopecia. While we found oral eplerenone to be safe and effective, further studies would be required before it can be routinely used in the population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-020-01499-6","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T17:02:40Z","timestamp":1591376560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone \u2013 a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-9390","authenticated-orcid":false,"given":"Ramesh","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpitha","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushagra","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"5","key":"1499_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1346-8138.1990.tb01641.x","volume":"17","author":"O Mori","year":"1990","unstructured":"Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17(5):276\u201381.","journal-title":"J Dermatol"},{"issue":"3 Pt 2","key":"1499_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0190-9622(87)70084-X","volume":"16","author":"H Uno","year":"1987","unstructured":"Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol. 1987;16(3 Pt 2):657\u201368.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1499_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","volume":"150","author":"AG Messenger","year":"2004","unstructured":"Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186\u201394.","journal-title":"Br J Dermatol"},{"key":"1499_CR4","doi-asserted-by":"crossref","unstructured":"Yum S, Jeong S, Kim D, Lee S, Kim W, Yoo J-W, et al. Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase. Int J Mol Sci. 2017;19(1).","DOI":"10.3390\/ijms19010053"},{"issue":"8","key":"1499_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF02505237","volume":"288","author":"S Lachgar","year":"1996","unstructured":"Lachgar S, Charv\u00e9ron M, Bouhaddioui N, Neveux Y, Gall Y, Bonaf\u00e9 JL. Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Arch Dermatol Res. 1996;288(8):469\u201373.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1499_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/1523-1747.ep12504905","volume":"95","author":"AE Buhl","year":"1990","unstructured":"Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553\u20137.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1499_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/187221312800166859","volume":"6","author":"A Rossi","year":"2012","unstructured":"Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Patents Inflamm Allergy Drug Discov. 2012;6(2):130\u20136.","journal-title":"Recent Patents Inflamm Allergy Drug Discov"},{"issue":"6","key":"1499_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/jps.2600790605","volume":"79","author":"JJ Ferry","year":"1990","unstructured":"Ferry JJ, Shepard JH, Szpunar GJ. Relationship between contact time of applied dose and percutaneous absorption of minoxidil from a topical solution. J Pharm Sci. 1990;79(6):483\u20136.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1499_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/15569527.2011.613427","volume":"31","author":"F Scarinci","year":"2012","unstructured":"Scarinci F, Mezzana P, Pasquini P, Colletti M, Cacciamani A. Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness. Cutan Ocul Toxicol. 2012;31(2):157\u20139.","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"1499_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/10799891003786234","volume":"30","author":"R Rastmanesh","year":"2010","unstructured":"Rastmanesh R. Alopecia and ocular alterations: a role for Minoxidil? J Recept Signal Transduct Res. 2010;30(3):189\u201392.","journal-title":"J Recept Signal Transduct Res"},{"issue":"2","key":"1499_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","volume":"86","author":"M Wang","year":"2008","unstructured":"Wang M, Munch IC, Hasler PW, Pr\u00fcnte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126\u201345.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1499_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","volume":"38","author":"E Rahimy","year":"2018","unstructured":"Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, et al. A randomized double-blind placebo-control pilot study of EPLERENONE for the treatment of central serous CHORIORETINOPATHY (ECSELSIOR). Retina Phila Pa. 2018;38(5):962\u20139.","journal-title":"Retina Phila Pa"},{"issue":"1","key":"1499_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","volume":"7","author":"I Zucchiatti","year":"2018","unstructured":"Zucchiatti I, Sacconi R, Parravano MC, Costanzo E, Querques L, Montorio D, et al. Eplerenone versus observation in the treatment of acute central serous Chorioretinopathy: a retrospective controlled study. Ophthalmol Ther. 2018;7(1):109\u201318.","journal-title":"Ophthalmol Ther"},{"issue":"10220","key":"1499_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2020;395(10220):294\u2013303.","journal-title":"Lancet Lond Engl"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:32:29Z","timestamp":1622835149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01499-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for utilising his clinical details for this manuscript. Permission for using the patient data for this report was obtained from Narayana Nethralaya institutional review board and ethics committee (C\/2019\/06\/03).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}